Nexavar tablets 200 mg for carcinoma (sorafenib tosylate, sorafenib tosilate)
What are Nexavar tablets 200 mg for carcinoma (sorafenibtosylate, sorafenib butilate)?
An active principle of Nexavar tablets is sorafenib butilate, a salt of sorafenib. This synthetic compound works by blocking the enzyme kinase regulating cell division and proliferation. As the result, Nexavar tablets inhibit tumor proliferation and vascularization.
Nexavar tablets are effective for the treatment of unresectable or metastatic renal cell carcinomas, unresectable liver cancer, and unresectable thyroid cancer. Sorafenib, a molecularly targeted agent, has a predictable and acceptable toxicity profile. It is also non-cross-resistant to other molecularly targeted drugs, so it can be used alone or in combination with other medications.
Active principles: sorafenib tosylate
Amount: 56 tablets
Maker: Bayer Yakuhin, Ltd., Osaka, Japan
- unresectable renal cell carcinoma,
- metastatic renal cell carcinoma,
- unresectable hepatocellular carcinoma,
- unresectable thyroid carcinoma.
How to take
Adults should take 2 tablets (400 mg of active principle) at a time, 2 times a day. Your doctor may reduce or increase the dosage according to your age, symptoms and response.
Contraindications: do not use for pregnant, possibly pregnant or breastfeeding women.
Due to the teratogenic effects, female patients should use effective contraception during the treatment and for some time after it.
As high-fat food may lower the level of this medicine in plasma and reduce its effect, avoid taking this medicine between 1 hour before and 2 hours after high-fat meals.
If an allergic reaction occurs, patient needs to stop using the medicine and consult with their doctor. If patient is taking any other medication or treatment, they should consult with their doctor in advance.